BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa

MAINZ, Germany, June 9, 2022 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) will welcome its African partners for the first time on the African continent and provide an update on the joint establishment of mRNA manufacturing facilities and vaccine development plans. The event will encompass the groundbreaking for BioNTech’s initial African mRNA manufacturing facility in Kigali, Rwanda, where the first BioNTainer modules are planned to be delivered by the end of 2022.

Following the invitation of H.E. President Paul Kagame of Rwanda, several heads of States and Government are expected to attend, alongside highest-level representatives from the African Union, the European Union, and WHO. The event will take place on June 23, 2022, at approx. 11.30 am CET / 05.30 am ET. A limited number of accredited media representatives will be able to join the event on-site. Interested journalists are invited to send an e-mail with the subject line “BioNTainer in Africa”.

In February 2022, BioNTech introduced its approach to establish scalable vaccine production by developing and delivering turnkey mRNA manufacturing facilities based on a container solution named “BioNTainer”. BioNTech also expects to ship BioNTainers to Senegal and potentially South Africa in close coordination with the respective country and the African Union.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

CONTACTS

Investor Relations
Sylke Maas, Ph.D.
VP Investor Relations & Strategy
Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de 

Media Relations
Jasmina Alatovic
VP Corporate Communications
Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385
E-mail: Media@biontech.de